Ad is loading...
FCO vs SPSK
FCO vs SPSK Comparison Chart
Loading...
Show more...
Show more...
View a ticker or compare two or three
VS
VS
FCO vs. SPSK commentary
Mar 05, 2025
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FCO is a Buy and SPSK is a Buy.
SUMMARIES
FUNDAMENTALS
Fundamentals
SPSK has more net assets: 287M vs. FCO (44.7M). FCO has a higher annual dividend yield than SPSK: FCO (4.205) vs SPSK (1.317). FCO was incepted earlier than SPSK: FCO (33 years) vs SPSK (5 years). FCO has a higher turnover SPSK (19.00) vs SPSK (19.00).
| FCO | SPSK | FCO / SPSK | |
| Gain YTD | 4.205 | 1.317 | 319% |
| Net Assets | 44.7M | 287M | 16% |
| Total Expense Ratio | N/A | N/A | - |
| Turnover | 35.00 | 19.00 | 184% |
| Yield | 5.66 | 2.98 | 190% |
| Fund Existence | 33 years | 5 years | - |
TECHNICAL ANALYSIS
Technical Analysis
| FCO | SPSK | |
|---|---|---|
| RSI ODDS (%) | 5 days ago 85% | N/A |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 28% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 48% |
| MACD ODDS (%) | 2 days ago 87% | N/A |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 61% |
| TrendMonth ODDS (%) | 2 days ago 82% | 2 days ago 61% |
| Advances ODDS (%) | 6 days ago 90% | 2 days ago 56% |
| Declines ODDS (%) | N/A | 23 days ago 56% |
| BollingerBands ODDS (%) | N/A | 2 days ago 35% |
| Aroon ODDS (%) | 2 days ago 88% | N/A |
View a ticker or compare two or three
VS
VS
Ad is loading...
Show more...
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| NRABX | 12.27 | N/A | N/A |
| Neuberger Berman Abs Ret Multi-Mgr R6 | |||
| SLARX | 26.30 | N/A | N/A |
| DWS Latin America Equity Inst | |||
| TIGAX | 23.39 | -0.21 | -0.89% |
| Thornburg International Growth A | |||
| BRMAX | 14.70 | -0.23 | -1.54% |
| iShares Russell Mid-Cap Index Inv A | |||
| JDEUX | 43.10 | -0.77 | -1.76% |
| JPMorgan US Research Enhanced Equity R6 | |||